Crinetics Pharmaceuticals
Tracked across 4 events · 86 articles · First seen Jul 06, 2026 · Last active Aug 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Crinetics is being acquired by Vertex for $85 per share, providing shareholders with a premium. Its key assets include approved drug Palsonify and late-stage candidate atumelnant.
Jul 06, 2026 · 34 articles
Business
Impact: Crinetics is being acquired by Vertex for $10 billion, adding endocrine disorder treatments to Vertex's portfolio. The deal is expected to close in Q3 and is likely to provide a significant premium to Crinetics shareholders.
Aug 03, 2026 · 7 articles
Regulatory
Monteverde & Associates PC, a securities class action firm, has launched and continued investigations into numerous proposed mergers and acquisitions on behalf of shareholders. The firm is examining the terms of transactions involving companies such…
Impact: Target of investigation regarding its sale to Vertex Pharmaceuticals; shareholders may receive $85 per share, but the inquiry could affect the deal.
Jul 20, 2026 · 20 articles
Business
Impact: Crinetics Pharmaceuticals was acquired by Vertex, contributing to the favorable M&A environment.
Jul 06, 2026 · 25 articles
Vertex Pharmaceuticals
acquisition target
↔
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is the target of an acquisition by Vertex Pharmaceutic
Vertex Pharmaceuticals
acquirer
↔
Crinetics Pharmaceuticals
Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion to
ERGEN INTELLIGENCE
Track Crinetics Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard